The number of confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in Italy has shown a gradual increase from 98 cases in 2024 to 104 cases in 2028. This represents a steady year-on-year growth, culminating in a 6.1% increase over five years. Considering a CAGR of approximately 1.5%, the data highlights a slow but persistent rise in cases. In 2023, the recorded number of cases was around 96, indicating an upward trend in subsequent years.
Future trends to watch for include:
- Emerging treatment approaches and government interventions.
- Changes in healthcare policies affecting TB control in Italy.
- Potential impacts of global health developments on local MDR-TB cases.
